Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets. - GreenMedInfo Summary
Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.
J Neuroimmunol. 2022 Jan 15 ;362:577787. Epub 2021 Dec 11. PMID: 34923373
Jie Song
Myasthenia Gravis (MG) is a T cell-driven, autoantibody-mediated disease. Here we show that oral Berberine (BBR) ameliorated clinical symptoms of experimental autoimmune myasthenia gravis(EAMG) rat model via decreasing the frequencies of Th1, Th17, Th1/17 cell subsets. JAK-STAT pathway was highlighted by transcriptomic analysis with EAMG mononuclear cells (MNCs). Surface plasmon resonance identified ligand binding interaction between BBR and JAK2, and electrostatic interaction was proposed by molecular dynamic simulation. Reduced phosphorylated JAK1/2/3 and STAT1/3 in MNCs from BBR-fed EAMG rats were demonstrated. These results suggest that BBR might improve EAMG by rebalancing T cell subsets through targeting JAK-STAT pathway.